Published • loading... • Updated
ADA: Safety Data Offset Efficacy for Survodutide
The drug cut weight and liver fat, but gastrointestinal side effects drove a 19% dropout rate versus 2.9% on placebo.
Summary by Pharmaphorum
10 Articles
10 Articles
The market for obesity drugs will grow to more than $100 billion by the end of the 2030s. The competition is correspondingly tough. Boehringer Ingelheim, a pharmaceutical company, now provides data for a medium that is not quite clear.
BT+2 Reposted by 2 other sources
Zealand Pharma plunged 22 percent Monday morning on news from the weekend's diabetes conference.
·Denmark
Read Full Article
The share of Danish Zealand Pharma was hit hard, as investors reacted negatively to new data on the experimental weight loss drug survodutide, despite the fact that the treatment was successful... Shares of a company with an experimental weight loss drug plunged 25% in one day - Side effects scared investors - ΙΝΑΦΤΕΜΟΠΟΡΙΚΙ
Coverage Details
Total News Sources10
Leaning Left1Leaning Right2Center3Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 17%
C 50%
R 33%
Factuality
To view factuality data please Upgrade to Premium
